Non-small cell lung cancer: Current status of chemoradiation for locally advanced disease and an update on susceptibility and prevention

Author(s):  
Élia Cipriano ◽  
◽  
Helena Magalhães ◽  
Fernanda Estevinho ◽  
◽  
...  

Background: In non -small cell lung cancer (NSCLC) elderly patients with advanced disease and without driver mutations, questions remain if they benefit from doublet chemotherapy (ChT) or single -agent ChT. Methods: A retrospective study characterizing elderly NSCLC patients with advanced disease. The primary endpoint was overall survival (OS) after doublet ChT and single -agent ChT, calculated using Kaplan -Meier method and Log Rank test. Results: Forty -six patients with locally advanced or metastatic disease were treated with ChT (22 with platinum- -based doublet ChT and 24 with single -agent ChT). With a median follow -up of 26.6 months (mo.), the median OS was 8.4 mo. in doublet ChT and 7.0 mo. in single‑agent ChT, p=0.441. Conclusions: There were no statistically significant differences in survival between platinum -based doublet and monotherapy ChT in our studied population.


2008 ◽  
Vol 68 (3) ◽  
pp. 222-232 ◽  
Author(s):  
Cesare Guida ◽  
Paolo Maione ◽  
Antonio Rossi ◽  
Marianna Bareschino ◽  
Clorinda Schettino ◽  
...  

2002 ◽  
Vol 29 (3 Suppl 12) ◽  
pp. 10-16 ◽  
Author(s):  
Angela Davies ◽  
David R. Gandara ◽  
Primo Lara ◽  
Zelanna Goldberg ◽  
Peter Roberts ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document